DOI: 10.1055/s-00000069

Seminars in Liver Disease


A randomized, double-blind, multi-center phase III study of brivanib plus best supportive care (BSC) versus placebo plus BSC in Asian subjects with advanced hepatocellular carcinoma (HCC) who have failed or are intolerant to sorafenib (BRISK-APS).
Available at: . Accessed January 11, 2012

Download Bibliographical Data

Search in: